ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,048.42
-0.46%
Dow Jones
38,085.80
0.00%
US Dollar vs MXN
17.2678
0.37%
Brent Oil
88.675
0.60%
Bitcoin
64,375.84
-0.16%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NYSE
  6. Merck and Co Inc (MRK)

  7. Merck and Co Inc (MRK) Noticias

MRK Merck and Co Inc

130.72
0.00 (0.00%)
Pre Mercado
Última actualización: 06:36:18
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Merck and Co Inc MRK NYSE Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 130.72 06:36:18
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
130.72
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
25/4/202415:40IHMARKETNEWSU.S. Stocks Climb Well Off Worst Levels But Close Mostly..
25/4/202408:09IHMARKETNEWSFutures Pointing To Sharply Lower Open On Wall Street
25/4/202406:52IHMARKETNEWSSouthwest Shares Tumble 9.6% Post $231 Million 1Q Loss,..
25/4/202405:30BWMerck Announces First-Quarter 2024 Financial Results
19/4/202406:04PRNCAHealth Canada Approves KEYTRUDA® as a first-line treatment..
10/4/202406:13IHMARKETNEWSDelta Generates US$37 Million Profit in Q1, Google and Intel..
04/4/202405:45BWMerck Initiates Phase 3 Clinical Trial of MK-1084, an..
03/4/202407:00BWREJOICE-Ovarian01 Phase 2/3 Trial of Raludotatug Deruxtecan..
01/4/202405:45BWMerck to Hold First-Quarter 2024 Sales and Earnings..
28/3/202405:45BWEuropean Commission Approves Merck’s KEYTRUDA®..
27/3/202405:54IHMARKETNEWSGameStop Shares Tumble 20% in Pre-Market Trading Amid..
26/3/202417:21BWFDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a..
21/3/202405:45BWMerck Provides Update on Phase 3 KEYLYNK-006 Trial..
19/3/202408:00BWMerck Announces Positive Data on V116, an Investigational,..
15/3/202415:23PRNUSFarmSee Ltd Announces the Completion of a Minority..
15/3/202405:45BWMerck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy..
13/3/202402:00BWMerck Announces Plans to Conduct Clinical Trials of a Novel..
11/3/202407:15BWMerck Completes Acquisition of Harpoon Therapeutics, Inc.
06/3/202409:25BWGilead and Merck Announce Phase 2 Data Showing an..
05/3/202408:03IHMARKETNEWSFutures Pointing To Continued Weakness On Wall Street
05/3/202405:45BWMerck to Participate in the Barclays 26th Annual Global..
04/3/202405:45BWMerck to Participate in the Leerink Partners Global..
27/2/202405:45BWMerck to Participate in the TD Cowen 44th Annual Health Care..
23/2/202405:20BWMerck Receives Positive EU CHMP Opinion for KEYTRUDA®..
20/2/202415:14EDGAR2Form 8-K - Current report
20/2/202405:45BWFDA Grants Priority Review to Merck's Application for..
15/2/202415:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/2/202415:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202415:40EDGAR2Form 144 - Report of proposed sale of securities
14/2/202415:30EDGAR2Form 144 - Report of proposed sale of securities
14/2/202415:24EDGAR2Form 144 - Report of proposed sale of securities
13/2/202415:50EDGAR2Form 144 - Report of proposed sale of securities
13/2/202415:48EDGAR2Form 144 - Report of proposed sale of securities
12/2/202415:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202406:05PRNCASanté Canada approuve KEYTRUDA®, en association avec le..
09/2/202415:06EDGAR2Form 144 - Report of proposed sale of securities
08/2/202415:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202406:00PRNCAMERCK CANADA ANNOUNCES COLLABORATION WITH VECTOR INSTITUTE..
07/2/202415:09EDGAR2Form 144 - Report of proposed sale of securities
05/2/202415:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/2/202405:33PRNUSElanco Announces Sale of Aqua Business for $1.3 Billion
02/2/202415:35EDGAR2Form 144 - Report of proposed sale of securities
02/2/202415:09EDGAR2Form 144 - Report of proposed sale of securities
02/2/202415:08EDGAR2Form 144 - Report of proposed sale of securities
02/2/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/2/202415:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/2/202405:39EDGAR2Form 8-K - Current report
01/2/202405:30BWMerck Announces Fourth-Quarter and Full-Year 2023 Financial..
27/1/202409:00BWMerck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Death..
26/1/202410:49EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..

Su Consulta Reciente

NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados